Director Colin Bond details AGMB stock option awards in Form 3

Rhea-AI Filing Summary

Agomab Therapeutics NV director Colin Michael Bond filed an initial Form 3 showing holdings of stock options over common shares. He holds options over 96,321 shares with a $3.1800 exercise price and 27,165 shares at $5.2600, both expiring on November 4, 2034, plus 27,921 shares at $14.2600 expiring on January 15, 2036. Footnotes explain that portions of these options vest over time, subject to continued service, that common shares may be represented by American Depositary Shares on a one‑for‑one basis, and that exercise prices are reported in U.S. dollars based on a stated euro conversion rate.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Bond Colin Michael

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 96,321 shares (Direct)

Footnotes (1)

1. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The common shares may be represented by American Depositary Shares, each of which currently represents one common share. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bond Colin Michael

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	11/04/2034	Common shares(2)	96,321	$3.18(3)	D
Stock Option (Right to Buy)	(1)	11/04/2034	Common shares(2)	27,165	$5.26(3)	D
Stock Option (Right to Buy)	(4)	01/15/2036	Common shares(2)	27,921	$14.26(3)	D

Explanation of Responses:

1. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 33% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Agomab Therapeutics (AGMB) Form 3 filing show?

The Form 3 shows director Colin Michael Bond’s initial beneficial ownership in Agomab Therapeutics. It discloses several stock option awards over common shares, including their exercise prices, expiration dates, and vesting terms tied to his continued service with the company.

How many Agomab Therapeutics (AGMB) shares are covered by Colin Bond’s options?

Colin Bond’s options cover 96,321 underlying common shares at $3.1800, 27,165 shares at $5.2600, and 27,921 shares at $14.2600. These figures represent potential future share ownership if the options vest and are exercised according to their stated terms.

What are the key vesting terms in the Agomab Therapeutics (AGMB) Form 3?

The filing notes that 50% of one option vested on February 9, 2026, with the rest vesting monthly over 24 months, and another option vests 33% on February 9, 2027, then monthly thereafter. All vesting requires Colin Bond’s continued service on each vesting date.

How are Agomab Therapeutics (AGMB) exercise prices presented in the Form 3?

Exercise prices are reported in U.S. dollars and reflect conversion from euros at $1.1478 per EUR 1.00 as of March 16, 2026. This ensures comparable pricing information for U.S. investors reviewing the stock option awards disclosed in the filing.

Can Agomab Therapeutics (AGMB) common shares be held as ADSs?

Yes. The filing states that Agomab’s common shares may be represented by American Depositary Shares, with each ADS currently representing one common share. This structure allows investors to hold and trade the company’s equity on U.S. markets through ADSs.